한글목차

원발성 담즙성 담관염 치료 시장은 2025년에는 7억 6,940만 달러, 2032년에는 13억 8,850만 달러에 이르고, 2025-2032년 CAGR 8.8%를 보일 것으로 예측됩니다.

원발성 담즙성 담관염(PBC)은 간의 소담관을 침범하는 만성 자가면역성 간질환입니다. 질병이 진행되면 담관으로 알려진 담관에 흉터와 손상이 생겨 담즙이 간에서 자유롭게 흐르지 못하게 되어 시간이 지남에 따라 간을 손상시킵니다. PBC의 주요 증상으로는 피로, 가려움증, 황달 등이 있습니다. PBC를 치료하지 않고 방치하면 결국 간경변이나 간부전으로 이어질 수 있습니다. 원발성 담즙성 담관염 치료 시장은 이 질환의 병인과 진행에 관여하는 다양한 경로를 표적으로 하는 약물로 구성되어 있습니다. 우르소데옥시콜산(UDCA)은 여전히 1차 선택약이지만, 많은 환자들이 충분한 효과를 얻지 못하거나 불내성이 있는 경우가 많습니다. 미충족 수요에 대응하기 위해 오베티콜산이나 피브린산 유도체와 같은 2차 치료제가 부상하고 있습니다.

시장 역학

원발성 담즙성 담관염 치료 시장은 주로 전 세계 PBC 유병률 증가에 의해 주도되고 있습니다. 다양한 추정에 따르면, PBC의 전 세계 유병률은 100만 명당 40-400명입니다. 또한, 기존 치료제보다 더 높은 효능과 우수한 내약성 프로파일을 가진 새로운 2차 치료제의 출시도 시장을 견인하고 있습니다. 그러나 신약의 높은 비용, 시장에서의 PBC에 대한 낮은 인식 등이 개발을 억제하는 요인으로 작용하고 있습니다. 새로운 작용기전을 가진 파이프라인 의약품의 출현은 이 시장 진출기업들에게 좋은 기회가 될 것입니다. 효율적이고 안전한 치료법이 규제 당국의 승인을 받으면 난치성 환자들의 요구를 충족시킬 수 있을 것입니다.

본 조사의 주요 특징

• 세계의 원발성 담즙성 담관염 치료제 시장을 상세하게 분석했으며, 2024년을 기준 연도로 하여 2025-2032년까지의 예측 기간 시장 규모(미국 미얀마)와 연평균 성장률(CAGR)을 조사하여 전해드립니다.
• 또한, 다양한 부문에 걸친 잠재적인 수익 성장 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 주요 고찰을 제공합니다.
• 세계 원발성 담즙성 담관염 치료제 시장의 주요 기업 프로파일을 기업 개요, 제품 포트폴리오, 주요 특징, 주요 성과, 전략 등 다양한 매개 변수를 기반으로 정리하여 수록하였습니다.
• 주요 조사 대상 기업으로는 Intercept Pharmaceuticals, Inc. NW BIoTherapeutics, Merck & Co Inc., Ipsen Pharma, Johnson & Johnson, GENFIT, Ironwood Pharmaceuticals, Inc. 등이 있습니다.
• 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
• 세계 원발성 담즙성 담관염 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 참가자, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 원발성 담즙성 담관염 치료 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.

목차

제1장 조사 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map (COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
• 영향 분석
• 규제 시나리오
• 제품 발매/승인
• PEST 분석
• Porter's Five Forces 분석
• 인수합병(M&A) 시나리오

제4장 원발성 담즙성 담관염 치료 시장, 치료 유형별, 2020-2032년

• 서론
• Ursodeoxycholic Acid (UDCA)
• Obeticholic Acid (Ocaliva)
• Others (Fibrates (Tricor), 기타)

제5장 원발성 담즙성 담관염 치료 시장, 유통 채널별, 2020-2032년

• 서론
• 병원 약국
• 소매 약국
• 온라인 약국

제6장 원발성 담즙성 담관염 치료 시장, 지역별, 2020-2032년

• 서론
• 북미
  • 미국
  • 캐나다
• 유럽
  • 독일
  • 영국
  • 스페인
  • 프랑스
  • 이탈리아
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 인도
  • 중국
  • 일본
  • 호주
  • ASEAN 국가
  • 한국
  • 기타 아시아태평양
• 라틴아메리카
  • 브라질
  • 아르헨티나
  • 멕시코
  • 기타 라틴아메리카
• 중동
  • GCC 국가
  • 이스라엘
  • 기타 중동
• 아프리카
  • 북아프리카
  • 중앙아프리카
  • 남아프리카공화국

제7장 경쟁 구도

• Intercept Pharmaceuticals, Inc.
• Highlight Therapeutics, S.L.
• GSK plc.
• Bristol-Myers Squibb and Company
• Enanta Pharmaceuticals
• NW BIoTherapeutics
• Merck & Co Inc.
• Ipsen Pharma
• Johnson & Johnson
• GENFIT
• Ironwood Pharmaceuticals, Inc.
• Novartis AG
• COUR Pharmaceuticals
• Kaken Pharmaceutical Co., Ltd.

제8장 섹션

• 조사 방법
• 출판사에 대해

영문목차

Primary Biliary Cholangitis Treatment Market is estimated to be valued at USD 769.4 Mn in 2025 and is expected to reach USD 1,388.5 Mn by 2032, growing at a compound annual growth rate (CAGR) of 8.8% from 2025 to 2032.

Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease that affects the small bile ducts in the liver. As the disease progresses, it causes scarring and injury to these bile ducts, known as bile ductules, which stops bile from flowing freely within the liver and damaging it over time. Some key symptoms of PBC include fatigue, itching, and jaundice. If left untreated, PBC can eventually result in cirrhosis or liver failure. The primary biliary cholangitis treatment market consists of drugs that target various pathways involved in the pathogenesis and progression of the disease. Ursodeoxycholic acid (UDCA) remains the first-line treatment but many patients do not adequately respond or are intolerant to it. Second-line treatments such as obeticholic acid and fibric acid derivatives are emerging to address the unmet needs.

Market Dynamics

The primary biliary cholangitis treatment market is primarily driven by the rising prevalence of PBC globally. According to various estimates, the global prevalence of PBC ranges between 40 and 400 cases per million. The market is also propelled by the launch of novel second-line treatment options with higher efficacy and better tolerability profiles than conventional therapies. However, the market growth can be restrained by the high costs of newer drugs and lack of awareness about PBC in developing regions. Emergence of pipeline drugs with novel mechanisms of action represents an opportunity for players in this market. Regulatory approval of efficient and safe therapies can help address the needs of refractory patients.

Key Features of the Study

• This report provides an in-depth analysis of the global primary biliary cholangitis treatment market, and provides market size (US Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global primary biliary cholangitis treatment market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• The key companies covered as a part of this study include Intercept Pharmaceuticals, Inc., Highlight Therapeutics, S.L., GSK plc., Bristol-Myers Squibb and Company, Enanta Pharmaceuticals, NW Biotherapeutics, Merck & Co Inc., Ipsen Pharma, Johnson & Johnson, GENFIT, Ironwood Pharmaceuticals, Inc., Novartis AG, COUR Pharmaceuticals, and Kaken Pharmaceutical Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global primary biliary cholangitis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary biliary cholangitis treatment market.

Market Segmentation

• By Treatment Type
  • Ursodeoxycholic Acid (UDCA)
  • Obeticholic Acid (Ocaliva)
  • Others (Fibrates (Tricor), etc.)
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Top Companies in the Primary Biliary Cholangitis Treatment Market
  • Intercept Pharmaceuticals, Inc.
  • Highlight Therapeutics, S.L.
  • GSK plc.
  • Bristol-Myers Squibb and Company
  • Enanta Pharmaceuticals
  • NW Biotherapeutics
  • Merck & Co Inc.
  • Ipsen Pharma
  • Johnson & Johnson
  • GENFIT
  • Ironwood Pharmaceuticals, Inc.
  • Novartis AG
  • COUR Pharmaceuticals
  • Kaken Pharmaceutical Co., Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Primary Billiary Cholangitis Treatment, By Treatment Type
  • Market Primary Billiary Cholangitis Treatment, By Distribution Channel
  • Market Primary Billiary Cholangitis Treatment, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Increasing Prevalence of Primary Biliary Cholangitis
  • Growing Adoption of Novel Drugs
  • Increasing adoption of Combination Therapy
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Primary Biliary Cholangitis Treatment Market, By Treatment Type, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Ursodeoxycholic Acid (UDCA)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Obeticholic Acid (Ocaliva)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Others (Fibrates (Tricor), etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Primary Biliary Cholangitis Treatment Market, By Distribution Channel, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Primary Biliary Cholangitis Treatment Market, By Region, 2020-2032, (USD Mn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • India
    • China
    • Japan
    • Australia
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

7. Competitive Landscape

• Intercept Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Highlight Therapeutics, S.L.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GSK plc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Enanta Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• NW Biotherapeutics
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Merck & Co Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Ipsen Pharma
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GENFIT
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Ironwood Pharmaceuticals, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• COUR Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Kaken Pharmaceutical Co., Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Analyst Views

8. Section

• Research Methodology
• About us